Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
  • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
  • C07H5/10—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium to sulfur
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7016—Disaccharides, e.g. lactose, lactulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/06—Preparations for care of the skin for countering cellulitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• the present invention relates to calcium octasulphate sucroses, processes for their preparation and their use in the pharmaceutical and / or cosmetic field.
• Oligosaccharides are carbohydrates whose hydrolysis produces only simple sugars (oses). They are constituted by the union of at least two simple sugar molecules. Among the oligosaccharides, there is sucrose formed by the condensation of two monosaccharides: a glucose molecule and a fructose molecule.
• Sulfated oligosaccharides are known in the literature and have multiple biological, cosmetic and / or therapeutic activities.
• the application WO2006 / 017752 describes a method of treating inflammation of the airways using sulfated oligosaccharides as active substances.
• sulfated oligosaccharides as active substances.
• US5767104 discloses sulfated oligosaccharides, mainly aluminum sucrose octasulfate, in the treatment of alopecia.
• sucrose octasulfate is used as active ingredient in the treatment of gastric ulcers for its healing / healing properties.
• FR 2,646,604 describes formulations of sucrose octasulfate of aluminum, or sucralfate, with anti-inflammatory and healing properties, intended for the treatment of wounds or other ulcerous inflammations.
• WO 1994/00476 discloses a method of treating lesions and / or inflammations of the digestive tract by administering a sulfated sucrose salt, more particularly sucrose octasulfate of potassium or sodium.
• FR 1390007 describes the topical use of formulations containing sucralfate in combination with copper and zinc sulfate as tissue regenerators, healing and soothing.
• EP0230023 describes the use of polysulfated oligosaccharides, more particularly potassium sucrose octasulfate, as an agent for healing wounds.
• polysulfated oligosaccharides more particularly potassium sucrose octasulfate.
• the problems of healing are found in a large number of pathologies, accidents or follow surgery. There is therefore a permanent need for alternative compositions to improve healing and / or accelerate.
• the inventors have obtained novel compounds having surprising repairing, antimicrobial and anti-radical properties. Indeed, it has been unexpectedly shown that these compounds induce the migration of keratinocytes, the synthesis of hyaluronic acid, the differentiation of keratinocytes and the synthesis of antimicrobial peptides, unlike other sucrose metal octasulfates. Thus, these compounds allow the repair of the skin, the healing of wounds and promote healing, and this, in a very effective manner. Moreover, the inventors have shown that these compounds can also be used in cosmetics to maintain the comfort and beauty of the skin
• FIG. 1 represents the induction of hyaluronic acid synthesis (in ng / ml) with 0.1 ⁇ M retinoic acid (control), 10 ⁇ M sucrose octasulfate Ca (SOS-Ca), sucrose Na octasulfate at 10 ⁇ (SOS-NA), sucrose octasulfate K at 10 ⁇ (SOS-K). Percentages indicate induction of synthesis over untreated control. * p ⁇ 0.05 compared to the untreated control
• the present invention relates in particular to compounds of the following general formula I,
• n is an integer
• Y represents OH, Cl, Br, I, NO 3 , C 6 H 5 O 7 , CH 3 CO 2 , CF 3 CO 2 or -OCH 3 .
• This compound is represented by the following formula III.
• This compound is represented by the following formula IV.
• This compound is represented by the following formula V.
• This compound is represented by the following formula VI.
• the compound of formula VI corresponds to a compound of formula I wherein n is 0.
• Y represents OH, Cl, Fr, I, NO 3 , C 6 H 5 O 7 , CH 3 CO 2, CF 3 CO 2 or -OCH 3.
• the compound according to the invention is in hydrated form.
• the present invention further relates to a process for the preparation of the compounds of general formula I as above, wherein 0 ⁇ n ⁇ 4, or even 0 ⁇ n ⁇ 3 ,.
• the invention relates to a process for the preparation of compounds of formula I according to the invention in which 0 ⁇ n ⁇ 4, or even 0 ⁇ n ⁇ 3, characterized in that it comprises the following steps:
• sucrose octasulfate at. contacting the acid form of sucrose octasulfate in solution, preferably in aqueous solution such as water, with a calcium salt to form calcium sucrose octasulfate, and
• the method according to the invention therefore comprises a first step a. wherein the acid form of sucrose octasulfate in solution is contacted with a calcium salt.
• sucrose octasulfate in acid form comprises sucrose octasulfate of formula VII:
• sucrose octasulfate in acid form bringing together the sucrose octasulfate in acid form and a calcium salt under conditions allowing their complexation.
• the calcium salt is dissolved in the solution of sucrose octasulfate in acid form.
• the relative amounts of sucrose octasulfate in acid form and the calcium salt in the solution are chosen so as to obtain the desired compound of formula I, that is to say in which 0 ⁇ n ⁇ 4 or even 0 ⁇ n ⁇ 3.
• the contact time between the sucrose octasulfate in acid form and the calcium salt may be determined by routine tests and will depend in particular on the nature of the calcium salt used. When the salt used is calcium hydroxide, the contact time will preferably be between 8 and 15 hours.
• the contacting will preferably be carried out with stirring, for example using a magnetic stirrer.
• the "calcium salt” according to the invention is preferably chosen from calcium mineral salts such as, for example, Ca (OH) 2 , CaO, CaCl 2 , CaBr 2 , CaCl 2 , Ca (N o 3 ) 2 or Ca (BF 4 ) 2 or organic calcium salts such as, for example, Ca (CH 3 CO 2 ) 2 , Ca (CF 3 CO 2 ) 2 , Ca 3 (C 6 H 5 O 7 ) 2 or Ca (CH 3) 3 0) 2 .
• the calcium salt according to the invention is calcium hydroxide Ca (OH) 2 .
• the mixture obtained after step a. may optionally be filtered, in particular to remove any remaining calcium salts.
• the method according to the invention comprises a second step b. wherein the calcium sucrose octasulfate obtained in step a. is recovered.
• recovery according to the invention is preferably meant to obtain a sucrose sucrose octasulfate calcium, optionally a crystal.
• the recovery according to the invention may be carried out by extraction / precipitation by adding a solvent to the mixture obtained in step a.
• the solvent is added to the aqueous solution obtained in step a. and is mixed with it. The whole is then decanted. The least dense phase containing the crystal is then recovered. This phase will preferably be washed with water and then lyophilized to obtain calcium sucrose octasulfate in solid form.
• the pH of the solution obtained in step a. is adjusted to basic pH, for example pH 9.
• the dense phase obtained after decantation may be dissolved in water and then precipitated again in the solvent. This dissolution and re-extraction in the solvent can be carried out as many times as necessary to obtain the purity and the desired yield of calcium sucrose octasulfate.
• Such a process for recovering calcium sucrose octasulfate is described in particular in the examples.
• the solvent will preferably be an organic solvent or a mixture of organic solvents such as for example acetone, ethanol, ethyl acetate, methyl isobutyl ketone or methyl ethyl ketone, preferably acetone or ethanol.
• Steps a. and B. are preferably carried out in the dark.
• sucrose octasulfate in solution used in step a the method according to the invention can be obtained in any way known to those skilled in the art.
• the sucrose octasulfate in acid form will be obtained from a sucrose octasulfate salt.
• sucrose octasulfate in acid form is obtained from a sucrose octasulfate salt by the following steps: al. dissolving in a solution, preferably an aqueous solution such as water, a sucrose octasulfate salt,
• sucrose octasulfate salt solution a2. desulfurization of the thus obtained sucrose octasulfate salt solution to form the acid form of sucrose octasulfate in solution.
• sucrose octasulfate salt may be chosen from all existing sucrose octasulfate salts such as, for example, alkali metal salts (such as, for example, potassium, sodium, lithium, etc.).
• the sucrose octasulfate salt is potassium sucrose octasulfate or sodium sucrose octasulfate.
• Step al. allows obtaining a solution of sucrose octasulfate salt.
• dissolution of the sucrose octasulfate salt is meant the dissolution of said compound.
• volume of solution such as water
• the dissolution is preferably carried out by stirring the salt in a solution, such as water, for example by means of a magnetic stirrer.
• the method according to the invention may also comprise a step a.2 in which the dissolved salt solution obtained in step a1. is desalified.
• dealting is meant dissociation in the sucrose octasulfate salt of the acid form of the sucrose octasulfate and the cation. This desalting step is followed by the recovery of the acid form of sucrose octasulfate. This step can be carried out by any technique known to those skilled in the art, in particular by passing through an ion exchange column.
• the passage over an ion exchange column of the solution containing the acid sucrose octasulfate can be carried out several times in order to eliminate all the cations which are originally associated with it.
• the ion exchange column preferably contains a cation exchange resin.
• the cation exchange resin is a sulfonic acid type resin (for example Amberlite TM).
• the method according to the invention will comprise or consist of the following steps: al. dissolving in a solution, preferably an aqueous solution such as water, a sucrose octasulfate salt,
• sucrose octasulfate salt solution a2. desulfurization of the thus obtained sucrose octasulfate salt solution to form the acid form of sucrose octasulfate in solution.
• calcium sucrose octasulfate is obtained directly from sucralfate.
• Sucralfate is first sulfated, for example in pyridine and then brought into the presence of a strong base, such as (Ca (OH) 2 ) for example.
• the present invention further relates to compositions comprising one or more compounds of formula (I) wherein 0 ⁇ n ⁇ 4 or even 0 ⁇ n ⁇ 3 and at least one pharmaceutically or cosmetologically acceptable excipient.
• the invention also relates to a medical device comprising one or more compounds of formula (I) in which 0 ⁇ n ⁇ 4 or even 0 ⁇ n ⁇ 3 and a pharmaceutically or cosmetically acceptable excipient.
• composition according to the invention or the medical device according to the invention will contain only one type of compounds of formula I, preferentially the compound of formula II.
• the "excipient" according to the invention may, for example, be alone or in combination one or more surfactants, one or more solvents, one or more water-soluble polymers, one or more thickeners or gelling agents, one or more preservatives, one or more antibacterial agents, one or more antiseptics, one or more cicatrizing agents, one or more antioxidant agents, one or more emollient and / or moisturizing agents, one or more pigments, one or more perfumes and / or one or more dyes, agents for pH adjustment such as salts, acids, bases.
• compositions which produce no adverse, allergic or other adverse reactions when administered to an animal or a human.
• the exact composition and the form of the composition according to the invention may be determined by those skilled in the art depending on the use and the route of administration envisaged for the composition.
• composition according to the invention will preferably be formulated so that it can be administered topically or orally.
• topical administration includes skin applications, oral applications (oral mucosa), genital applications (anal mucosa, vaginal).
• oral administration includes in particular administrations by ingestion (including gastric).
• the composition When the composition is formulated so that it can be administered topically, it will preferably be in a form allowing an easy application such as a powder, a milk, a cream, a balm, an oil, a lotion, a gel or a mousse. , a foaming gel, an ointment, a spray, a paste, a patch, etc.
• the composition according to the invention may be in the form of a suppository, ovum or capsule.
• composition When the composition is formulated so that it can be administered in oral form it will preferably be in the form of a gum, a lozenge, a tablet, a boiled sugar, a drinking gel, a powder to dissolve, a gastric bandage, etc.
• the dosages of the compounds of formula (I) in which 0 ⁇ n ⁇ 4, or even 0 ⁇ n ⁇ 3, in the compositions will in particular be determined as a function of the quantity of active substance necessary to obtain the desired therapeutic and / or cosmetic response, depending on the intended mode of administration and the duration of the desired treatment.
• the composition according to the invention has a calcium sucrose octasulfate content according to the general formula I of between 0.1 and 30% by weight.
• the composition according to the invention for example for a topical application, will comprise between 0.5 and 7%, more preferably between 0.5 and 5% by weight of calcium sucrose octasulfate.
• the composition according to the invention may further comprise at least one other active ingredient, preferably another scarring agent, a painkiller, an anti-radical agent, an antiseptic and / or an anti-inflammatory agent.
• the present invention further relates to compounds according to the invention or compositions according to the invention for their use as medicaments.
• the present invention further relates to the use of a compound of formula (I) in which 0 ⁇ n ⁇ 4 or even 0 ⁇ n ⁇ 3, or a composition according to the invention for the manufacture of a drug.
• the present invention further relates to a method of treatment comprising administering to a patient in need thereof an effective dose of compounds of formula (I) wherein 0 ⁇ n ⁇ 4, or even 0 ⁇ n ⁇ 3 , or compositions according to the invention
• the compounds of formula (I) in which 0 ⁇ n ⁇ 4, or even 0 ⁇ n ⁇ 3, or compositions according to the invention are used for the treatment of the skin, mucous membranes or organs, more preferably to promote the cicatrisation of the skin, mucous membranes or organs and / or to protect them from microbial infections and / or to fight against microbial infections and / or to fight against inflammation.
• cicatrization is meant in particular the phenomena of regeneration and consolidation of tissues or organs to fill a lesion.
• promoting healing it is meant in particular that the cicatrization is done more rapidly and / or more effectively (absence or reduction of scars, etc.) in the presence of the compound or of a composition according to the invention.
• the use according to the invention will concern the cicatrization of acute or chronic wounds and burns.
• the expression "acute or chronic wound” comprises, in particular, abrasions, scrapes, scratches, cuts, canker sores, various wounds in the oral sphere, scar acne, blisters, cheilites eczema, diaper rash, dermatoporosis, eg gastric or leg ulcers, pressure ulcers, diabetic sores (especially feet), various irritations, dermatitis or scars after surgery or post dermatological procedure aesthetic (laser, hair removal, peeling, injection).
• burn includes burns of any origin including thermal, mechanical, chemical or radiation burns.
• the burns according to the invention may especially be burns due to heat or sunburn, radiodermites, cryotherapy scars, scars after surgery or after cosmetic dermatology act (laser, hair removal, peeling).
• Microbial infection means all skin or mucosal infections whether due to bacteria, yeasts, fungi or viruses.
• the compositions according to the invention may be used for preventive purposes to prevent the appearance of a microbial or therapeutic infection to fight against an already existing microbial infection.
• inflammation is meant an immune response of the body to an aggression characterized in particular by redness, swelling, feeling of heat and pain.
• the present invention particularly relates to the treatment of inflammatory conditions of the skin.
• sucralfate The amount of sucralfate to be administered to a patient will depend on the pathology to be treated and the mode of administration. For example, when a gastric application is envisaged, sucrose octasulfate calcium may be administered at a dose of 1 to 10 g / day, preferably 2 to 6 g / day.
• the present invention further relates to the use of a compound of formula (I) in which 0 ⁇ n ⁇ 4 or even 0 ⁇ n ⁇ 3, or a cosmetic composition according to the invention to improve the appearance of the skin.
• improving the appearance of the skin means the aesthetic improvement or comfort of a skin condition and / or mucous membranes.
• the aesthetic degradation of the skin condition or its comfort may be due for example to age, external conditions or weight variations.
• the cosmetic composition according to the invention may make it possible to restore the barrier function of the skin, the hydration of the skin, the increase of its elasticity and / or its tonicity and also the reduction of stretch marks, of cellulite or wrinkles and the disappearance of skin spots.
• the compound or the composition according to the invention may be used to prevent skin aging.
• the following examples are given for illustrative purposes and do not limit the scope of the invention.
• the mixture is then filtered and 500 ml of acetone are added to the filtrate.
• the resulting mixture is allowed to stand overnight.
• the supernatant is decanted and the remaining syrup is dissolved in 15 ml of demineralised water, and 200 ml of acetone is added to the solution.
• the resulting mixture is allowed to stand for 3 hours and the supernatant is decanted. Such an operation is repeated 3 times.
• the syrup is dissolved in 30 ml of water and the mixture is lyophilized. A white sucrose octasulfate calcium solid is obtained (0.50 g, 38%).
• sucrose octasulfate and calcium contained in the compound II obtained is carried out.
• the same assay is carried out in control samples having a known Ca or sucrose octasulfate concentration: CaC12 and potassium sucrose octasulfate (SOS-K). The dosage is carried out as follows:
• Table 1 Estimation of the Ca concentration of the SOS-Ca samples according to a CaCl 2 standard.
• the ratio calcium / sucrose octasulfate in the compound of formula II SOS-Ca obtained is 3.2443 / 0.8237, or 3.94 which corresponds well to the expected ratio.
• EXAMPLE 2 Effect of Ca Sucrose Octasulfate on Cell Migration Epithelial cell migration is an important step in the development and processes of tissue repair, such as embryogenesis and wound healing.
• keratinocytes are "activated" to undertake the process of migration.
• the cells then see their phenotype influenced by interactions with the extracellular matrix on the one hand and by cell-cell interactions on the other hand.
• the keratinocytes of the basal seat of the banks of a wound migrate on the wound and cover it.
• the keratinocyte line used is the HaCaT human keratinocyte line, spontaneously immortalized. This line is frequently cited as a reference model in the literature.
• the protocol used for the study of cell migration is based on the use of a 96-well kit, Oris Cell Migration Assay (Platypus Technologies - TEBU), allowing the miniaturization and quantification of this cellular process.
• the principle of this test is to study cell migration to the well center of the 96-well plate. It involves placing a stopper in wells to create a detection zone of 2 mm in diameter. Then remove the stoppers once the cells have adhered to the surface around them, and thus allow the cells to migrate to the detection zone. Plates without stoppers and with active ingredients are incubated at 37 ° C for 24 hours in DMEM 0% FCS. The amount of cells located in the area where the stopper was then analyzed for cell migration. A cache is used to view and count only cells in this area. For each condition, the average of 6 to 8 wells is achieved.
• the products tested in this study are the SOS-Ca obtained in Example 1 at 10 ⁇ , SOS-K at 10 ⁇ (Sucrose octasulfate potassium), SOS-Na at 10 ⁇ (Sucrose octasulfate sodium) and EGF as a positive witness. A negative control is carried out in which no compound is added to the culture medium.
• sucrose octasulfate potassium (SOS-K) and sucrose octasulfate sodium (SOS-Na) do not induce the migration of keratinocytes.
• sucrose octasulphate calcium (SOS-Ca) statistically significantly induces the migration of keratinocytes.
• SOS-Ca can significantly induce the migration of keratinocytes unlike SOS-K and SOS-Na.
• Example 3 Effect of Ca Sucrose Octasulfate on Cell Differentiation
• the epidermis plays a major protective role in providing a chemical and mechanical barrier for the body. It ensures the maintenance of the seal, namely the skin barrier function. Corneocytes, keratinocytes of the stratum corneum, associated with a lipid matrix, largely ensure this function. Nevertheless the deeper layers intervene in the setting up of the actors of this function. The differentiation capacity of the keratinocytes of the epidermis will guarantee the establishment of a barrier of selective functional permeability type.
• Keratinocytes are spatiotemporally regulated, evolving from the deepest layers of the epidermis, the least differentiated basal layer, to the stratum corneum, the ultimate stage of differentiation of keratinocytes into corneocytes. From a protein point of view, the epidermal differentiation is mainly focused on the evolution of structural proteins that are keratins and that contribute to the architectural integrity of the epidermis. Their expression varies according to the degree of maturation of the keratinocytes. Basic keratin 1 and acidic keratin 1 are early markers of keratinocyte differentiation present in the basal layer of the epidermis.
• transglutaminases such as transglutaminase 1 (TGM1) or 3.
• Loricrin is a structural protein containing glutamine and lysine residues for attachment to other proteins in the horny envelope.
• the basic filaggrin molecules (FLG) produced from its precursor profilaggrin (stored in the keratohyaline granules) associate with the cytokeratin filaments, thus allowing their aggregation.
• Filaggrin can then be removed by the enzymes Peptidyl Arginine Deiminase (PAD) and in particular PAD 1 and PAD3.
• PAD Peptidyl Arginine Deiminase
• PAD Peptidyl Arginine Deiminase
• PAD Peptidyl Arginine Deiminase
• keratinocyte lipids are at the origin of the intercorneocyte lipid cement essential for the cutaneous barrier, the formation of which represents the final phase of epidermal terminal differentiation.
• This extracellular lipid matrix provides the main barrier to transcutaneous movements of water and electrolytes.
• a number of enzymes and lipid transporters have their keratinocyte expression increased with differentiation.
• This cement results from a balance between three lipid species, the cholesterol, free fatty acids and ceramides. These lipids are derived from glucosylceramides, sphingomyelin, cholesterol and phospholipids synthesized in the spinous and granular layers.
• the lamellar bodies contain numerous enzymes including lipid hydrolases such as Acid Sphyngomyelinase (aSmase), beta- glucocerebrosidase (GBA) or Plospholipase A2 (sPLA2) as well as acidic and neutral lipases.
• lipid hydrolases such as Acid Sphyngomyelinase (aSmase), beta- glucocerebrosidase (GBA) or Plospholipase A2 (sPLA2) as well as acidic and neutral lipases.
• the barrier function of the skin also includes a defense against microorganisms.
• the epithelium plays an active role in the innate defenses of the host.
• Skin antimicrobial systems are based, among other things, on the presence of certain surface lipids (oleic and palmitoleic acids of sebum and of certain constituent proteins which are increasingly expressed as a function of the differentiation state of keratinocytes (R Ase 7, proteinase Inhibitor 3) Rase 7 and inhibitory proteinase 3 (PI3 or elafin) possess antimicrobial activities, Rnase 7 is a member of the Rnase A family and has broad-spectrum antimicrobial activity. against Gram + or Gram - bacteria.
• acidification of the epidermal surface plays an important role in cutaneous antimicrobial defenses.
• the skin thus acts not only as a physical barrier, but also as a chemical barrier.
• these antimicrobial peptides link the innate and adaptive immune response. They play an important role as mediators of inflammation by having effects on epithelial and inflammatory cells, influencing cell proliferation, scarring, cytokine production, chemokines and chemotaxis.
• Antimicrobial peptides are generally synthesized in the upper layers of the spinous layer and the granular layer, but they are active in the stratum corneum where they are released. Their mode of action is to disrupt the plasma membrane of infectious microbes or to enter the microorganism to interfere with intracellular metabolism.
• the most studied antimicrobial peptides in the skin are ⁇ -defensins and cathelicidines.
• Human ⁇ -defensins are the major class of antimicrobial peptides found in human epithelia and four of them have been identified in the skin, hBD 1-4. Although they belong to the same family, they are regulated by different voices.
• hBD-2 Human ⁇ -defensin 2 (hBD-2 or DEFB4), a 4 kDa peptide binding to heparin, is one of the major cutaneous antimicrobial peptides. Only bacteriostatic against S. aureus, hBD-2 has antimicrobial activity primarily directed against Gram-negative bacteria.
• ⁇ -Defensin 3 (hBD-3), a 5 kDa antimicrobial peptide, has broad-spectrum antimicrobial activity including Staphylococcus aureus.
• Psoriasin belongs to the S100 family of proteins, named after its discovery from psoriasis dander extracts. This 1 1 kDa peptide is in particular produced in cutaneous zones where bacterial colonization is abundant as well as in inflammatory zones. It is mainly directed against Escherichia coll.
• the keratinocyte line used is the line of primary human keratinocytes or NHKs prepared from skin flaps from cosmetic surgery surgical waste (breast reduction).
• test products are incubated with the keratinocytes for 72 hours.
• the cells are then recovered and an analysis of the expression of target genes involved in epidermal differentiation by real-time PCR is performed.
• the products tested are SOS-Ca at 10 ⁇ or 30 ⁇ , SOS-Na at 10 ⁇ or 30 ⁇ , SOS-K at 10 ⁇ or 30 ⁇ , and CaCl 2 at 1.5 mM as a positive control.
• a negative control is carried out in which no product is added to the culture medium.
• S100A7 49 49 133 50 59 205 884 binding protein A7 Table 4: expression of genes involved in cell differentiation in an NHKs keratinocyte line after incubation with SOS-Ca at 10 ⁇ or 30 ⁇ , SOS-Na at 10 ⁇ or 30 ⁇ , SOS-K at 10 ⁇ or 30 ⁇ M or CaCl 2 at 1.5 mM as a percentage of the expression of the different mRNAs relative to the negative control.
• SOS-Ca strongly induced the expression of differentiation markers.
• SOS-K and SOS-Na at 30 ⁇ induced differentiation of keratinocytes in a moderate manner. It can be seen that at 30 ⁇ , SOS-K and SOS-Na induce 8 and 11 targets, respectively, whereas SOS-Ca induces 17. Moreover, the induction of the expression of all genes is stronger by SOS-Ca than with the other two SOS.
• SOS-Ca induced the expression of protein markers of differentiation, proteins involved in lipid synthesis (such as KLK7), involved in desquamation, and induced the expression of antimicrobial peptides like hBD2 (DEFB4). , PB and psoriasin (S100A7).
• SOS-Ca By inducing the expression of Fabaggrin and Padil, SOS-Ca also participates in the synthesis of natural hydration factor.
• SOS-Ca therefore plays a very important role in the differentiation of keratinocytes and activates the physical protein barrier function, lipid and antimicrobial and cutaneous hydration.
• EXAMPLE 4 Effect of Ca Sucrose Octasulfate on the Synthesis of Hyaluronic Acid
• Hyaluronic acid is a component of the extracellular matrix that can be synthesized by keratinocytes and has many functions.
• hyaluronic acid is involved in maintaining cutaneous hydration, proliferation and stimulation of cellular motility during re-epithelialization.
• the amount of hyaluronic acid present at the cutaneous level decreases with age, which is partly responsible for skin aging.
• the keratinocyte line used is the line of primary human keratinocytes or NHKs, prepared from skin flaps from surgical plastic surgery waste (breast reduction).
• test products are incubated with the keratinocytes for 72 hours.
• the culture supernatants are then recovered and an analysis of hyaluronic acid expression is performed by the Duoset Hyaluronan ELISA Kit (ReD Systems) according to the supplier's instructions.
• the products tested are SOS-Ca at 10 ⁇ , SOS-Na at 10 ⁇ , SOS-K at 10 ⁇ , and retinoic acid at 0.1 ⁇ as a positive control.
• a negative control is carried out in which no product is added to the culture medium.
• the values of the amount of hyaluronic acid obtained are shown in FIG. 1 as a percentage of induction relative to the untreated negative control.
• 0.1 ⁇ l retinoic acid a positive control, induced the synthesis of hyaluronic acid by 80%.
• SOS-K and Na do not induce an increase in hyaluronic acid synthesis.
• SOS-Ca therefore plays an important role in the induction of hyaluronic acid synthesis and thus in the hydration and prevention of cutaneous aging.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Birds (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Cosmetics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=46197284

Family Applications (1)

Country Status (3)

Cited By (1)

Citations (10)

• 2011
  • 2011-05-31 FR FR1154757A patent/FR2975994B1/fr not_active Expired - Fee Related
• 2012
  • 2012-05-31 WO PCT/EP2012/060314 patent/WO2012164047A1/fr active Application Filing
  • 2012-05-31 EP EP12724651.0A patent/EP2714706A1/de not_active Withdrawn

Patent Citations (11)

Also Published As

Similar Documents

Legal Events